Could adding a second diabetes drug early save lives?

NCT ID NCT07465926

Completed Knowledge-focused Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study analyzed health records from over 450,000 adults with obesity and type 2 diabetes to see if adding a GLP-1 or SGLT2 drug early improves survival and kidney health. Researchers compared those who added the other drug class within 90 days to those who added a different drug or no early add-on. The goal was to see if early combination therapy reduces death and heart or kidney problems over three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to: If results are positive, this could suggest that adding a second drug early improves survival and kidney health in people with obesity and type 2 diabetes.
What could go wrong: This is an observational study using existing records, not a controlled trial. It can show links but cannot prove cause and effect. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE RISK FACTOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular-kidney-metabolic syndrome impaired renal function disease kidney disorder Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE RISK FACTOR CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME KIDNEY DISEASE OBESITY & OVERWEIGHT TYPE 2 DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.